Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase IV Study of Telbivudine in Chinese Patients with Chronic Hepatitis B
2016-001444-20Phase 4
- Sponsor
- Novartis
- Start
- May 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telbivudine in Chronic Hepatitis B (CHB), sponsored by Novartis. Primary endpoint: HBV DNA PCR negativity rate at week 52 (primary).
02
Drugs
telbivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2016-001444-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001444-20.